Swiss Banks Stock News

European Medicines Agency’s CHMP issues a positive opinion on remibrutinib for adults with chronic spontaneous urticaria who do not respond adequately to standard therapies. CHMP recommendation is based on clinical trial data and represents a key regulatory step for SWX:NOVN in allergic and immunological conditions. Novartis announces plans for a new radioligand therapy manufacturing site in Texas to support production of cancer therapies in the US. Novartis, traded as SWX:NOVN, is a large...

If you are wondering whether Sandoz Group is still attractively priced after its recent run, this article will help you size up what you are really paying for each Swiss franc of the business. The shares closed at CHF64.66, with a 7.0% return over the last month, a 13.0% return year to date, and a 71.1% return over the past year, although the last 7 days saw an 8.1% decline that may have changed how some investors view the risk and reward trade off. Recent news flow around Sandoz Group has...

Galderma Group (SWX:GALD) reports full year sales above $5b, marking a milestone for its dermatology focused portfolio. The company highlights new product launches it describes as having blockbuster potential across its prescription and aesthetics segments. Fresh clinical data show Nemluvio delivering long term efficacy and safety in prurigo nodularis, an area of high unmet medical need. Regulatory approval of new device technology supports further expansion of Galderma's aesthetics...

Adecco Group (SWX:ADEN) shares are in focus after the company reported fourth quarter and full year 2025 results, along with upcoming Board changes that include planned departures and a defined end date for the current Chair. See our latest analysis for Adecco Group. The earnings and Board updates come after a weaker share price patch, with a 1-day share price return of 2.03% at CHF21.06, compared with a year-to-date share price return of 10.23% and a 1-year total shareholder return of...

How VAT Group’s FY 2025 Numbers Set Up the Next Chapter VAT Group (SWX:VACN) has wrapped up FY 2025 with second half revenue of CHF 515.6 million and basic EPS of CHF 3.63, alongside trailing twelve month revenue of CHF 1.07 billion and EPS of CHF 7.15 framing the latest print. Over recent periods, the company has seen half yearly revenue move from CHF 492.6 million in 2H 2024 to CHF 515.6 million in 2H 2025, while half yearly EPS shifted from CHF 3.92 to CHF 3.63, and trailing twelve month...

What the latest earnings tell you about Zug Estates Holding Zug Estates Holding (SWX:ZUGN) just released full year 2025 figures, with sales of CHF 87.72 million, revenue of CHF 91.5 million, and net income of CHF 85.18 million drawing fresh investor attention. These headline numbers give you a fresh reference point for thinking about the stock, its current valuation, and how the business is converting its real estate and hotel activities into bottom line results. See our latest analysis for...

HIAG Immobilien Holding FY 2025 earnings snapshot HIAG Immobilien Holding (SWX:HIAG) has just posted its FY 2025 numbers, with first half revenue of CHF 47.6 million and basic EPS of CHF 4.42, while funds from operations came in at CHF 1.90 per share, giving investors a fresh read on both cash generation and headline profitability. Over recent periods the company has seen revenue move from CHF 70.3 million in the first half of 2024 to CHF 65.8 million in the second half of 2024 and then to...

What Holcim’s 2025 earnings mean for shareholders Holcim (SWX:HOLN) has moved into focus after reporting full year 2025 results, with sales of CHF 15,724 million compared to CHF 16,201 million a year earlier, and a sharp jump in reported net income and earnings per share. See our latest analysis for Holcim. Despite the strong headline earnings, Holcim’s 1 month share price return of an 18.15% decline and a 14% share price pullback year to date suggest momentum has cooled, even as the 1 year...

Implenia (SWX:IMPN) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 1.9b and basic EPS of CHF 1.80 setting the tone for how the year is shaping up. The company has seen revenue move from CHF 1.7b in the first half of 2024 to CHF 1.9b in the latest half, while basic EPS shifted from CHF 1.43 to CHF 1.80 over the same periods, creating a results season in which investors are weighing growth prospects against how efficiently those sales are turning into profit. See...

What Swisscom’s Recent Share Performance Tells You Swisscom (SWX:SCMN) has seen its share price move in recent weeks, with a 0.8% decline over the past day contrasting with gains over the past week, month and past 3 months. For context, the stock shows a 0.9% return over the past week, 12.3% over the past month and 28.2% over the past 3 months, with a 45.7% total return over the past year. See our latest analysis for Swisscom. The recent pullback in Swisscom’s share price to CHF714.5 comes...

Why Siegfried Holding’s latest earnings and leadership moves matter now Siegfried Holding (SWX:SFZN) has just released its full year 2025 results alongside a senior management reshuffle, a combination that gives you fresh information on both the business performance and how the company is being run. See our latest analysis for Siegfried Holding. The latest CHF82.5 share price comes after a 14.4% 90 day share price return and 10.4% year to date gain, even though the 1 year total shareholder...

SoftwareOne Holding (SWX:SWON) has been appointed one of the first global authorized Google Cloud distributors, with new distribution rights across 10 launch markets and extended support for partners using Google Cloud services. See our latest analysis for SoftwareOne Holding. The new Google Cloud distribution role arrives after a tough stretch for the share price, with a 30 day share price return of a 13.28% decline and a 90 day share price return of a 23.32% decline, even as the 1 year...

Why Sensirion’s upcoming earnings are on investors’ radar Sensirion Holding (SWX:SENS) is drawing attention ahead of its 10 March 2026 earnings release, as investors watch how demand for sensors in AI and IoT devices shows up in the latest numbers. The focus is on how the company’s cash position and R&D spending support its role as a potential growth play in AI related hardware, and whether new guidance shifts sentiment around the stock. See our latest analysis for Sensirion Holding. Despite...

Alcon (SWX:ALC) is in the spotlight after reporting fourth quarter 2025 earnings, with higher sales and revenue alongside lower net income, while also proposing a dividend and drawing attention for its intraocular lens business. See our latest analysis for Alcon. Alcon’s share price is now at CHF65.24, with a 1 month share price return of 5.29% and a year to date share price return of 2.68%. The 1 year total shareholder return of 21.63% decline contrasts with modest 3 year and 5 year total...

In February 2026, Swiss Re reported full-year 2025 net income of US$4,740 million, sharply higher than the prior year, and announced a share repurchase program of up to US$1.50 billion authorized by its Board, running through December 31, 2026 subject to legal and regulatory approvals. Together with the appointment of Anne Lohbeck as chief risk officer for PC Re, these moves highlight Swiss Re's focus on capital return and risk oversight alongside improved profitability. We’ll now examine...

Kuehne + Nagel International (SWX:KNIN) FY 2025 Results: Margins In Focus After Softer Q4 Kuehne + Nagel International (SWX:KNIN) has wrapped up FY 2025 with fourth quarter revenue of CHF5.95b and basic EPS of CHF1.32, alongside net income of CHF157m. These results frame how investors may assess the full year at a share price of CHF180.45. The company’s quarterly revenue moved from CHF6.76b in Q4 2024 to CHF6.33b in Q1 2025 and then to CHF5.95b in Q4 2025, while basic EPS shifted from CHF2.50...

Roche Holding (SWX:ROG) is back in focus after Genentech reported that fenebrutinib met the primary endpoint in the pivotal Phase III FENhance 1 trial in relapsing multiple sclerosis, with statistically significant efficacy versus teriflunomide. See our latest analysis for Roche Holding. The fenebrutinib update lands after a series of drug pipeline milestones and conference appearances. It comes with a 90 day share price return of 15.7% and a 1 year total shareholder return of 22.3%, which...

Amrize (SWX:AMRZ) has introduced its new EVERtect™ high-performance concrete range for customers in North America. The portfolio includes multiple specialized mixes tailored for different construction uses across the U.S. and Canada. The launch expands Amrize’s presence in high-spec concrete solutions for both structural and low-carbon applications. For you as an investor, this move highlights how Amrize is positioning its core materials business around more differentiated, higher-spec...

If you are wondering whether ABB's current share price still makes sense after a strong run, this article breaks down what you are really paying for the business today. ABB shares last closed at CHF 67.20, with returns of 46.1% over 1 year and 181.5% over 5 years. The shorter term picture is mixed, with a 4.8% decline over 7 days but a 9.7% gain year to date. Recent headlines have focused on ABB's ongoing position as a major player in electrification and automation, as well as its exposure...

Alcon reports that more than 175 million of its intraocular lenses have been implanted worldwide. The milestone highlights broad adoption of the company’s presbyopia-correcting IOLs across global eye care practices. Alcon plans further intraocular lens launches, subject to regulatory approvals. For investors following Alcon (SWX:ALC), this update comes with the shares trading at CHF63.96 and a value score of 4. The stock shows a 22.3% decline over the past year, while 3-year and 5-year...

On 24 February 2026, Iconovo AB announced it had signed a Letter of Intent with Lonza Group to pursue a long-term collaboration around spray dried formulation capabilities for inhalable biologics, building on their existing work on an obesity project. This potential alliance links Lonza’s CDMO scale with Iconovo’s five-platform inhaler technology targeting biologics and high-value respiratory franchises with global turnover of about US$9.00 billion. We’ll now examine how this focus on spray...

Avolta AG recently completed the cancellation of about 4.9 million treasury shares, reducing its registered share capital to CHF 708,241,695 across 141,648,339 shares, while continuing to expand its food and beverage footprint at key airports in Italy and Canada. This combination of a tighter share base and integrated travel retail and dining growth highlights Avolta’s focus on capital efficiency alongside strengthening its airport partner relationships. Next, we’ll examine how Avolta’s...

Zurich Insurance Group has confirmed the acquisition of UK based insurer Beazley, following completion of an accelerated equity offering to fund the deal. The transaction expands Zurich's presence in international insurance markets and follows investor backing via fresh equity capital. The company, trading as SWX:ZURN, remains in focus as integration plans and capital impacts come into view for shareholders. Zurich Insurance Group, ticker SWX:ZURN, is approaching this deal with a current...

Sandoz Group (SWX:SDZ) has received EU marketing authorization for Ranluspec. The approval expands the company’s biosimilars portfolio into the ophthalmology segment. The decision supports an expected product launch later in 2026 across European markets. For you as an investor, this represents a business development in a high-value area of medicine. Sandoz focuses on biosimilars and generics, and Ranluspec adds another product aimed at chronic eye conditions where long-term treatment is...